Edition:
United Kingdom

Bill Berkrot

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

10 Oct 2017

Pharma's Puerto Rico problems could mean drug shortages: FDA chief

NEW YORK The head of the U.S. Food and Drug Administration said on Tuesday the country may start to see a small number of drug shortages within two or three weeks due to delays in restoring manufacturing operations in Puerto Rico, where 10 percent of drugs prescribed in the United States are made.

10 Oct 2017

Pharma's Puerto Rico problems could mean drug shortages -FDA chief

NEW YORK, Oct 10 The head of the U.S. Food and Drug Administration said on Tuesday the country may start to see a small number of drug shortages within two or three weeks due to delays in restoring manufacturing operations in Puerto Rico, where 10 percent of drugs prescribed in the United States are made.

28 Sep 2017

Eli Lilly wins U.S. approval for breast cancer drug

The U.S. Food and Drug Administration said on Thursday it approved an Eli Lilly and Co drug to treat advanced breast cancer that has progressed following prior treatment.

28 Sep 2017

AbbVie, Amgen settlement sets Humira U.S. biosimilar launch for 2023

Amgen Inc has reached a settlement with AbbVie Inc that will delay the U.S. launch of Amgen's cheaper biosimilar version of AbbVie's cash cow, the blockbuster rheumatoid arthritis drug Humira, until Jan. 31, 2023.

13 Sep 2017

'Impressed' FDA panel unanimously recommends GSK shingles vaccine

A U.S. Food and Drug Administration advisory panel on Wednesday voted 11-0 that the safety and efficacy of GlaxoSmithKline's Shingrix shingles vaccine warrants approval for its use in adults aged 50 and over.

10 Sep 2017

Lilly takes on Pfizer, Novartis with new breast cancer drug data

NEW YORK/MADRID Eli Lilly staked its claim for a slice of sales in a new class of breast cancer drugs on Sunday as clinical data showed adding its medicine abemaciclib to standard therapy reduced the risk of disease progression by 46 percent.

09 Sep 2017

Lilly drug cuts risk of advanced breast cancer progression -study

Sept 9 An experimental Eli Lilly and Co drug taken with standard therapy reduced the risk of disease progression by 46 percent versus standard therapy alone in women not previously treated for advanced breast cancer, according to interim data from a late stage study presented at a medical meeting.

07 Sep 2017

Quest to offer cholesterol testing without fasting requirement

Quest Diagnostics Inc said on Thursday it will begin using a more precise method of calculating levels of "bad" LDL cholesterol that no longer requires fasting prior to blood draw, a development likely to delight patients who previously had to refrain from eating for up to 12 hours before testing.

31 Aug 2017

Novartis gene therapy approval signals new cancer treatment era

Novartis AG on Wednesday won highly anticipated U.S. approval for the first of a new type of potent gene-modifying immunotherapy for leukemia, a $475,000 treatment that marks the start of a potential new treatment paradigm for some cancers.

03 Aug 2017

PerkinElmer profit meets Street view, boosts 2017 forecast range

Scientific instruments maker PerkinElmer Inc on Thursday posted a second-quarter profit that matched expectations and boosted its full-year earnings forecast range with a new midpoint slightly ahead of Wall Street estimates.

  • Europe
  • U.S.
  • Asia
  • Sectors
Stock Search
FTSE 100 7,526.97 -8.47 -0.11%
DAX 13,003.70 + 11.83 +0.09%
CAC 40 5,362.88 + 11.14 +0.21%
TR Europe 185.72 -0.34 -0.18%
GBP/USD 1.3283 -0.01%
GBP/EUR 1.1245 -0.10%
EUR/USD 1.1808 -0.12%
Gold 1,303.20 +1.70 +0.13%
Oil 51.89 +0.44 +0.86%
Corn 351.00 -1.75 -0.50%